# Study of SNX-5422 in TP53 Null Cancers

> **NCT02612285** · PHASE2 · TERMINATED · sponsor: **Esanex Inc.** · enrollment: 1 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** SNX-5422

## Key facts

- **NCT ID:** NCT02612285
- **Lead sponsor:** Esanex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Recruitment very slow - study could not be enrolled
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612285, "Study of SNX-5422 in TP53 Null Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02612285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*